Form 4 for TSHA Taysha Gene Therapies, Inc.
Accepted 2024-05-31 00:00:00 ET · period of report 2024-05-29 · accession 0001415889-24-015041 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-05-31 | 2024-05-29 | TSHA | Stalfort John A III | Dir | A - Grant | $0.00 | +49.2K | 1.10M | +5% | $0 |
| D | 2024-05-31 | 2024-05-29 | TSHA | Stalfort John A III | Dir | A - Grant | $0.00 | +98.4K | 98.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-29 | A | A | 49,220 | $0.00 | 1,098,601 | D | — | — | (F1) Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2024-05-29 | A | A | 98,440 | $0.00 | 98,440 | D | $3.17 · — to 2034-05-29 | 98,440 Common Stock | (F3) The shares vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |